OBJECTIVE: Insulin resistance, the underlying pathophysiological mechanism of the metabolic syndrome, can not only predict type 2 diabetes development but also cardiovascular disease. Thus, precise insulin resistance measurement in individuals at risk for metabolic diseases would support clinical risk stratification. However, the gold standard for measuring insulin resistance, the hyperinsulinemic clamp test, is too labor intensive to be performed in large clinical studies/settings. RESEARCH DESIGN AND METHODS: Using plasma glucose and C-peptide concentrations from oral glucose tolerance tests (OGTTs), we developed the novel "clamp-like index" (CLIX) for insulin sensitivity calculation and compared CLIX to clamp glucose infusion rates (GIR) (100-120 min). We evaluated CLIX in 89 nondiabetic subjects (58 female and 31 male, aged 45 +/- 1 years, BMI 27.5 +/- 0.8 kg/m(2)) who underwent frequently sampled 3-h 75-g OGTTs and 2-h hyperinsulinemic-isoglycemic clamp (40 mU/min per m(2)) tests. RESULTS: CLIX, calculated as serum creatinine (x0.85 if male)/(mean AUC(glucose) x mean AUC(C-peptide)) x 6,600, was highly correlated (r = 0.670, P < 10(-12)) with and comparable to clamp GIRs(100-120 min). In subgroup analyses, GIRs(100-120 min) were lower (P < 0.005) in type 2 diabetic offspring (6.2 +/- 0.7 mg x min(-1) x kg(-1)) than in sex-, age-, and BMI-matched subjects without a family history of type 2 diabetes (8.6 +/- 0.5 mg x min(-1) x kg(-1)), which was also reflected by CLIX (insulin-resistant offspring 6.4 +/- 0.6 vs. those without a family history of type 2 diabetes 9.0 +/- 0.5; P < 0.002). When compared with normal-weight subjects (GIR 8.8 +/- 0.4 mg x min(-1) x kg(-1); CLIX 9.0 +/- 0.5), both GIRs(100-120 min) and CLIX of obese (5.2 +/- 0.9 mg x min (-1) x kg(-1); 5.7 +/- 0.9) and morbidly obese (2.4 +/- 0.4 mg x min (-1) x kg(-1); 3.3 +/- 0.5) humans were lower (each P < 0.02). CONCLUSIONS: CLIX, a novel index obtained from plasma OGTT glucose and C-peptide levels and serum creatinine, without inclusion of anthropometrical measures to calculate insulin sensitivity in nondiabetic humans, highly correlates with clamp GIRs and reveals even slight insulin sensitivity alterations over a broad BMI range and is as sensitive as the hyperinsulinemic clamp test.
OBJECTIVE:Insulin resistance, the underlying pathophysiological mechanism of the metabolic syndrome, can not only predict type 2 diabetes development but also cardiovascular disease. Thus, precise insulin resistance measurement in individuals at risk for metabolic diseases would support clinical risk stratification. However, the gold standard for measuring insulin resistance, the hyperinsulinemic clamp test, is too labor intensive to be performed in large clinical studies/settings. RESEARCH DESIGN AND METHODS: Using plasma glucose and C-peptide concentrations from oral glucose tolerance tests (OGTTs), we developed the novel "clamp-like index" (CLIX) for insulin sensitivity calculation and compared CLIX to clamp glucose infusion rates (GIR) (100-120 min). We evaluated CLIX in 89 nondiabetic subjects (58 female and 31 male, aged 45 +/- 1 years, BMI 27.5 +/- 0.8 kg/m(2)) who underwent frequently sampled 3-h 75-g OGTTs and 2-h hyperinsulinemic-isoglycemic clamp (40 mU/min per m(2)) tests. RESULTS:CLIX, calculated as serum creatinine (x0.85 if male)/(mean AUC(glucose) x mean AUC(C-peptide)) x 6,600, was highly correlated (r = 0.670, P < 10(-12)) with and comparable to clamp GIRs(100-120 min). In subgroup analyses, GIRs(100-120 min) were lower (P < 0.005) in type 2 diabetic offspring (6.2 +/- 0.7 mg x min(-1) x kg(-1)) than in sex-, age-, and BMI-matched subjects without a family history of type 2 diabetes (8.6 +/- 0.5 mg x min(-1) x kg(-1)), which was also reflected by CLIX (insulin-resistant offspring 6.4 +/- 0.6 vs. those without a family history of type 2 diabetes 9.0 +/- 0.5; P < 0.002). When compared with normal-weight subjects (GIR 8.8 +/- 0.4 mg x min(-1) x kg(-1); CLIX 9.0 +/- 0.5), both GIRs(100-120 min) and CLIX of obese (5.2 +/- 0.9 mg x min (-1) x kg(-1); 5.7 +/- 0.9) and morbidly obese (2.4 +/- 0.4 mg x min (-1) x kg(-1); 3.3 +/- 0.5) humans were lower (each P < 0.02). CONCLUSIONS:CLIX, a novel index obtained from plasma OGTT glucose and C-peptide levels and serum creatinine, without inclusion of anthropometrical measures to calculate insulin sensitivity in nondiabetic humans, highly correlates with clamp GIRs and reveals even slight insulin sensitivity alterations over a broad BMI range and is as sensitive as the hyperinsulinemic clamp test.
Authors: M Krššák; Y Winhofer; C Göbl; M Bischof; G Reiter; A Kautzky-Willer; A Luger; M Krebs; C Anderwald Journal: Diabetologia Date: 2011-04-15 Impact factor: 10.122
Authors: Ziad S Mahmassani; Paul T Reidy; Alec I McKenzie; Chris Stubben; Michael T Howard; Micah J Drummond Journal: J Appl Physiol (1985) Date: 2019-02-14
Authors: Draženka Janković; Peter Wolf; Christian-Heinz Anderwald; Yvonne Winhofer; Miriam Promintzer-Schifferl; Astrid Hofer; Felix Langer; Gerhard Prager; Bernhard Ludvik; Alois Gessl; Anton Luger; Michael Krebs Journal: Obes Surg Date: 2012-01 Impact factor: 4.129
Authors: Paul T Reidy; Catherine C Lindsay; Alec I McKenzie; Christopher S Fry; Mark A Supiano; Robin L Marcus; Paul C LaStayo; Micah J Drummond Journal: Exp Gerontol Date: 2017-07-10 Impact factor: 4.032
Authors: Jonathan J Petrocelli; Alec I McKenzie; Ziad S Mahmassani; Paul T Reidy; Gregory J Stoddard; Annelise M Poss; William L Holland; Scott A Summers; Micah J Drummond Journal: J Gerontol A Biol Sci Med Sci Date: 2020-09-16 Impact factor: 6.053
Authors: Marietta Stadler; Christian Anderwald; Giovanni Pacini; Stefan Zbýn; Miriam Promintzer-Schifferl; Martina Mandl; Martin Bischof; Stephan Gruber; Peter Nowotny; Anton Luger; Rudolf Prager; Michael Krebs Journal: Diabetes Date: 2009-10-15 Impact factor: 9.461
Authors: Stefan Traussnigg; Emina Halilbasic; Harald Hofer; Petra Munda; Tatjana Stojakovic; Günter Fauler; Karl Kashofer; Martin Krssak; Michael Wolzt; Michael Trauner Journal: Wien Klin Wochenschr Date: 2020-09-15 Impact factor: 1.704
Authors: Christian-Heinz Anderwald; Andrea Tura; Miriam Promintzer-Schifferl; Gerhard Prager; Marietta Stadler; Bernhard Ludvik; Harald Esterbauer; Martin Georg Bischof; Anton Luger; Giovanni Pacini; Michael Krebs Journal: Diabetes Care Date: 2012-08-24 Impact factor: 19.112